 CARLSBAD, Calif.--BUSINESS WIRE--- LCTX LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter 2021. Lineage will host a conference call today at 4:30 p.m. Eastern Time to discuss its second quarter 2021 financial results and to provide a business update. Lineage continued to make significant operational and developmental 